Inspira Technologies OXY B.H.N. Ltd. has unveiled an exclusive in-house capability designed to simulate both the arterial and venous blood parameters of patients with specific medical conditions without the need of in vivo animal testing. This platform has played, and will continue to play, a vital role in advancing the development of HYLA Blood Sensor and VORTX Orbiting blood oxygenation delivery system, which are the core technologies of the Inspira ART500. Using unique methods and equipment, team of scientists has the ability to simulate human blood conditions based on a predefined medical profile.

The proprietary setting allows the management of blood parameters continuously and in real-time for a range of blood flow rates in order to simulate a patient's oxygen-deficient and carbon dioxide-rich blood after it has flowed through body organs and tissues. The company believe that these break-through capabilities may enable to further expand research within a shorter timeframe and with a better use of resources, thereby reducing time and costs. The increased access to data is an important contributing factor towards efforts to accelerate the development, testing and release of new technologies and products as well as for more advanced verification and validation prior to regulatory submissions.

This platform allows Inspira Technologies to control the blood parameters over a wide range, allowing it to test the efficacy and accuracy of its technologies in key scenarios, such as simulating the blood parameters of patients who may suffer from acute medical conditions. The Company's high-end lab capabilities include the means for monitoring oxygen and carbon dioxide levels and detecting hemolysis and other key parameters and elements under extreme conditions.